Cited by 887Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Open access

Collet, Jean-Philippe, Cuisset, Thomas, Rangé, Grégoire, Cayla, Guillaume, Elhadad, Simon, Pouillot, Christophe, Henry, Patrick, Motreff, Pascal, Carrié, Didier, Boueri, Ziad, Belle, Loic, Van Belle, Eric, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A., Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Barthélémy, Olivier, Beygui, Farzin, Silvain, Johanne, Vicaut, Eric, Montalescot, Gilles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1209979

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1209979

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Guidelines on myocardial revascularization
Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,228
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,311
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D. J., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,158
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R. C., Bhatt, D. L., Cattaneo, M., Collet, J., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,151
Self-citation
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H. M., Harmsze, A. M., der Heyden, J. A. S. V., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Mehta, S. R., Tanguay, J., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H., Budaj, A., Avezum, Á., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 812
Self-citation
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citation

Show all 26 references

Sorted by citations

Items 501–600 of 883

Clinical Outcome of First‐ vs Second‐Generation DES According to DAPT Duration: Results of ARCTIC ‐Generation
Collet, J., Silvain, J., Kernéis, M., Cuisset, T., Meneveau, N. F., Boueri, Z., Barthélémy, O., Rangé, G., Cayla, G., BELLE, E. V., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22512 · Cited by 7
Self-citation
Personalizing antiplatelet therapies: What have we learned from recent trials?
Landry, S., Tanguay, J., & Lordkipanidzé, M. (2017) · Platelets · doi:10.1080/09537104.2017.1320372 · Cited by 7
Medikamentenfreisetzende Koronarstents/-scaffolds und medikamentenbeschichtete Ballonkatheter
NEF, H. M., Abdel‐Wahab, M., Achenbach, S. S., Joner, M., Levenson, B., Mehilli, J., Möllmann, H., Thiele, H., Zahn, R., Zeus, T., et al. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0202-9 · Cited by 7
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications
Gorog, D. A. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1641-2 · Cited by 7
Intensified P2Y12 inhibition for high-on treatment platelet reactivity
Mshelbwala, F. S., Hugenberg, D. W., & Kreutz, R. P. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02075-x · Cited by 7
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients
Cheng, D., Zhao, S., & Hao, Y. (2020) · Bioscience Reports · doi:10.1042/bsr20201346 · Cited by 7
PLATELET FUNCTION TEST FOR THE ASSESSMENT OF THROMBOSIS AND BLEEDING RISK IN CHD PATIENTS TAKING ANTIPLATELET MEDICATIONS
Komarov, A. L., & Панченко, Е. П. (2015) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2015-2-25-34 · Cited by 7
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2)
Asher, E., Abu‐Much, A., Goldenberg, I., Segev, A., Sabbag, A., Mazin, I., Shlezinger, M., Atar, S., Zahger, D., Pollak, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157437 · Cited by 7
Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation
Tello‐Montoliu, A., Rivera, J., Hernández, D., Nicolas-Silvente, A. I., Jover, E., Rodríguez, A. I. E., Quintana, M., Romero, A., Orenes‐Piñero, E., Rivera‐Caravaca, J. M., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0471 · Cited by 7
Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome
Tilemann, L. M., Mohr, S. K., Preusch, M. R., Chorianopoulos, E., Giannitsis, E., Katus, H. A., & Müller, O. J. (2017) · Journal of Interventional Cardiology · doi:10.1111/joic.12474 · Cited by 7
Are Immature Platelets Growing Up?
Kleiman, N. S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.055 · Cited by 7
Nutzenbewertung personalisierter Interventionen: Methodische Herausforderungen und Lösungsansätze
Windeler, J., & Lange, S. (2013) · Ethik in der Medizin · doi:10.1007/s00481-013-0269-1 · Cited by 6
Recent advances in antithrombotic therapy after acute coronary syndrome
Matteau, A., & Bhatt, D. L. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130506 · Cited by 6
Managing Clopidogrel Resistance in Neurointervention: Surveying Current Approaches
Kim, H. W., Bach, I., Gutierrez, J. C. M., Dmytriw, A. A., D’Amato, S. A., Zeineddine, H. A., Yoo, A. J., & Sheth, S. A. (2024) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.124.001324 · Cited by 6
CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition
Cuisset, T., & Quilici, J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9442-z · Cited by 6
Self-citation
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss–of function polymorphisms (*2/*3)
Chikata, Y., Iwata, H., Osborn, E. A., Fukuda, K., Okai, I., Shiozaki, M., Kimura, Y., Inoue, K., Fujiwara, Y., & Sumiyoshi, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.067 · Cited by 6
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Malik, A. H., Gupta, R., Chakraborty, S., Mahajan, P., Bandyopadhyay, D., Yandrapalli, S., Zaid, S., Sreenivasan, J., Chaturvedi, A., Mehta, S. S., et al. (2022) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2022.01.005 · Cited by 6
Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis
Yamani, N., Unzek, S., Mankani, M. H., Almas, T., Musheer, A., Qamar, H., Farooq, S., Shahnawaz, W., Fatima, K., Figueredo, V. M., et al. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103964 · Cited by 6
Platelet Reactivity: Is There a Role to Switch?
Aradi, D., Merkely, B. P., & Komócsi, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.008 · Cited by 6
Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations
Karathanos, A., & Geisler, T. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0022-y · Cited by 6
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification
Price, M. J., Baker, B., Jakubowski, J. A., Li, W., Heiselman, D., & Angiolillo, D. J. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12505 · Cited by 6
Recent advances in antithrombotic treatment for acute coronary syndromes
Howard, J. P., Antoniou, S., Jones, D. A., & Wragg, A. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.923306 · Cited by 6
Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States
Wang, T. Y., Henry, T. D., McCoy, L. A., Berger, P. B., Cohen, D. J., Effron, M. B., Zettler, M. E., Baker, B., Messenger, J. C., & Peterson, E. D. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.06.021 · Cited by 6
Current Concepts in the Clinical Utility of Platelet Reactivity Testing
Collet, J. (2013) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2013.8.2.100 · Cited by 6
Self-citation
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
Ristorto, J., Messas, N., Marchandot, B., Kibler, M., Hess, S., Meyer, N., Schaeffer, M. W., Tuzin, N., Ohlmann, P., Jesel, L., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40584 · Cited by 6
Cardiovascular Risk Reduction
Smith, T. J., Johnson, J. L., Habtewold, A., & Burmeister, M. A. (2018) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2018.11.001 · Cited by 6
Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
Mshelbwala, F. S., Hugenberg, D. W., & Kreutz, R. P. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s242675 · Cited by 6
Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Muruganantham, S., Krishnaswami, V., Alagarsamy, S., & Kandasamy, R. (2020) · Current Drug Targets · doi:10.2174/1389450121666201027125303 · Cited by 6
Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention
Liu, R., Li, T., Yuan, D., Chen, Y., Tang, X., Gao, L., Zhang, C., Jia, S., Zhu, P., Xu, O., et al. (2022) · Journal of International Medical Research · doi:10.1177/03000605221081725 · Cited by 6
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients
Freeman, P. M., Moschonas, K., Hinz, C., O’Donnell, V. B., Kinnaird, T. D., James, P. E., & Anderson, R. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.024 · Cited by 6
High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures
Spiliοpoulos, S., Kassimis, G., Hatzidakis, A. A., & Krokidis, M. E. (2013) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-013-0707-y · Cited by 6
Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku
ESC, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0280 · Cited by 7
Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?
Dézsi, D. A., Merkely, B. P., Skopál, J., Barabás, E., Várnai, K., Faluközy, J., Veress, G., Alotti, N., & Aradi, D. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417728287 · Cited by 6
Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation
Bloemen, S., Zwaveling, S., Mullier, F., & Douxfils, J. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.09.037 · Cited by 6
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms
Zhang, Y., Zhao, X., Ye, Y., Li, Q., & Zeng, Y. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001164 · Cited by 6
Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy
Quatromoni, N., Tuteja, S., Kolansky, D. M., Matthai, W., & Giri, J. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0501-1 · Cited by 6
Low On‐Treatment Platelet Reactivity Predicts Long‐Term Risk of Bleeding After Elective PCI
Čolić, M., Čalija, B., Milosavljevic, B., Grdinić, A., Angelkov, L., Sagić, D., Kružliak, P., Marinković, J., Babić, R., & Mrdović, I. (2015) · Journal of Interventional Cardiology · doi:10.1111/joic.12251 · Cited by 6
Validation of a P2Y12-receptor specific whole blood platelet aggregation assay
Amann, M., Ferenc, M., Valina, C. M., Bömicke, T., Stratz, C., Leggewie, S., Trenk, D., Neumann, F., & Hochholzer, W. (2016) · Platelets · doi:10.3109/09537104.2016.1153620 · Cited by 6
Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes
Cornel, J. H., Ohman, E. M., Neely, B., Jakubowski, J. A., Bhatt, D. L., White, H. D., Ardissino, D., Fox, K. A. A., Prabhakaran, D., Armstrong, P. W., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003977 · Cited by 6
Antiplatelet Agents in Acute ST Elevation Myocardial Infarction
Kumar, K., & Golwala, H. B. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.042 · Cited by 5
Monitoring of Antiplatelet Therapy
Gurbel, P. A., & Tantry, U. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00030-4 · Cited by 5
Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel
Wan, H., Han, W., Wu, Z., Lie, Z., Li, D., & Su, S. (2020) · Platelets · doi:10.1080/09537104.2020.1817886 · Cited by 5
Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial
Wu, H., Song, H., Dou, L., Gao, B., Pan, Y., Dong, M., Chen, Q., Li, J., Song, L., Liu, C., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01974-z · Cited by 5
Antithrombotic strategies in elderly patients with acute coronary syndrome
Dillinger, J., Laine, M., Bouajila, S., Paganelli, F. F., Henry, P., & Bonello, L. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.12.002 · Cited by 5
Self-citation
In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor
Singam, N. S. V., Aladili, B. N., Amraotkar, A. R., Coulter, A. R., Singh, A., Kulkarni, S., Mitra, R., Daham, O. N., Smith, A. E., & DeFilippis, A. P. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107000 · Cited by 5
Impact of the PEAR 1 Polymorphism on Clinical Outcomes in Chinese Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Hu, X., Liu, C., Zhang, M., & Zhang, W. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0033 · Cited by 5
Clinical Outcomes of Individualized Antiplatelet Therapy Based on Platelet Function Test in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Peng, W., Zhang, Y., Lin, B., & Yang, L. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001393 · Cited by 5
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia
Silvain, J., Lattuca, B., Puymirat, É., Ducrocq, G., Dillinger, J., Lhermusier, T., Procopi, N., Cachanado, M., Drouet, É., Abergel, H., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad055 · Cited by 5
Self-citation
Antithrombotic Treatment in Coronary Artery Disease
Siasos, G., Tsigkou, V., Bletsa, E., Stampouloglou, P. K., Oikonomou, E. K., Kalogeras, K. I., Κατσαρού, Ο., Pesiridis, T., Vavuranakis, Μ., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230830105750 · Cited by 5
Platelet phenotypes and practical aspects of platelet function testing in cardiology
Kobalava, Z. D., Pisaryuk, A. S., Андреевна, Ф. А., Tukhsanboev, E. S., Boldyreva, A. A., Lazutova, D. P., Meray, I. A., & Panteleev, M. A. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2023-2981 · Cited by 5
Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH)
Wegerif, E. C. J., Ünlü, Ç., Generaal, M. I., van den Bor, R. M., van de Ven, P. M., Bots, M. L., & de Borst, G. J. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.04.001 · Cited by 5
Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?
Wong, C. K. (2013) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000e105 · Cited by 5
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.08.002 · Cited by 5
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know
Steiner, S., & Moertl, D. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.816120 · Cited by 5
Key Advances in Clinical Cardiology
Connolly, M., & Menown, I. B. A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0024-5 · Cited by 5
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status
Leoncini, M., Toso, A., Maioli, M., Angiolillo, D. J., Giusti, B., Marcucci, R., Abbate, R., & Bellandi, F. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0966-0 · Cited by 5
Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
Tomey, M. I., & Mehran, R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0405-z · Cited by 5
Impact of Tailored Anti-P2Y12 Therapies in Acute Coronary Syndromes
Stimpfle, F., & Geisler, T. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.19 · Cited by 5
Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry
Deharo, P., Loosveld, M., Bonnet, G., Pankert, M., Quilici, J., Lambert, M., Verdier, V., Morange, P., Bonnet, J., Alessi, M., et al. (2014) · IJC Heart & Vessels · doi:10.1016/j.ijchv.2014.04.005 · Cited by 5
Self-citation
Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack
Zhang, L.-L., Hu, X., Zhu, J.-H., Cai, X.-Y., Kong, Y., Wang, H., Diao, S.-S., Zhao, H.-R., Jiang, J.-H., Wang, D.-P., et al. (2017) · BioMed Research International · doi:10.1155/2017/3504950 · Cited by 5
Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity
Tornyos, A., Aradi, D., Horváth, I., Kónyi, A., Magyari, B., Pintér, T., Vorobcsuk, A., Tornyos, D., & Komócsi, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188493 · Cited by 5
Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy
Lattuca, B., Silvain, J., Yan, Y., Pouillot, C., Cuisset, T., Cayla, G., Henry, P., Diallo, A., Elhadad, S., Rangé, G., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007749 · Cited by 5
Self-citation
VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel
Gómez, J. M. C., Martínez, J. A., Benítez, C., de la Llera, L. S. D., Fernández-Quero, M., Rasco, A. G., Gil-Ortega, M. V., & Sánchez-González, Á. (2015) · Acta cardiologica. Supplementum · doi:10.1080/ac.70.6.3120187 · Cited by 5
A Sticky Situation: Variable Agreement Between Platelet Function Tests Used to Assess Anti-platelet Therapy Response
Nakahara, H., Sarker, T. T., Dean, C. L., Skukalek, S. L., Sniecinski, R. M., Cawley, C. M., Guarner, J., Duncan, A., & Maier, C. L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.899594 · Cited by 5
Platelet Rna As a Novel Biomarker for the Response to Antiplatelet Therapy
Voora, D., Ginsburg, G. S., & Åkerblom, A. (2013) · Future Cardiology · doi:10.2217/fca.13.90 · Cited by 5
Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel
Cattaneo, M. (2013) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328364bd3a · Cited by 5
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes
Su, T., Chan, Y., Lee, J.-D., Lee, M., Lin, L.-C., Wen, Y., & Lee, T. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.06.016 · Cited by 5
Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention
Golukhova, E. Z., Grigoryan, M. V., Николаевна, Р. М., & Bulaeva, N. I. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-5-528-535 · Cited by 5
Measuring high on-treatment platelet reactivity in clinical practice; should we use a panel of platelet function tests?
Zwart, B., Godschalk, T. C., Zheng, K., Denteneer, J., Kelder, J. C., & ten Berg, J. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000831 · Cited by 5
Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: Clinical significance of platelet reactivity unit and adjunctive cilostazol
Kim, G. J., Heo, Y., Moon, E. J., Park, W., Ahn, J. S., Lee, D. H., & Park, J. C. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107133 · Cited by 5
Antiplatelet Therapy in Coronary Artery Disease: Now and Then
Tscharre, M., & Gremmel, T. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1758821 · Cited by 5
Improved Ticagrelor Antiplatelet Effect on Discontinuation of Phenytoin
Weeks, P. A., Sieg, A. C., Vahdat, K. K., Raissi, F., & Nathan, S. S. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013520140 · Cited by 5
Carotid Endarterectomy on Antiplatelet Agents in the Era of Point-of-Care Testing
Moon, K., Nanaszko, M. J., Levitt, M. R., Gross, B. A., Zabramski, J. M., Spetzler, R. F., & Nakaji, P. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.05.080 · Cited by 5
Antiplatelet treatments
Vogel, B., & Baber, U. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000416 · Cited by 5
Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis
Hong, J. M., Turgeon, R. D., & Pearson, G. J. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019845334 · Cited by 5
The ABCD-GENE Score for Clopidogrel Response
Bittl, J. A. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.01.228 · Cited by 5
Prasugrel and ticagrelor
Morici, N., Colombo, P., Mafrici, A., Oreglia, J., Klugmann, S., & Savonitto, S. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328364561b · Cited by 4
From Arctic to Antarctic: Is There any Remaining Role for Platelet Function Testing to Tailor Therapy after Coronary Stent Implantation?
Wong, C. K. (2016) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000e132 · Cited by 4
Association of Age‐ and Body Mass Index‐Stratified High On‐Treatment Platelet Reactivity With Coronary Intervention Outcomes in East Asian Patients
Cha, J., Lee, S., Park, J. H., Hong, S. J., Ahn, T. H., Chang, K., Park, Y., Song, Y. B., Ahn, S. G., Suh, J., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031819 · Cited by 4
Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology
Elserwey, A., Jabbour, R. J., & Curzen, N. P. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2384217 · Cited by 4
Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial
Dillinger, J., Pezel, T., Batias-Moreau, L., Angoulvant, D., Goralski, M., Ferrari, É., Cayla, G., Silvain, J., Gilard, M., Lemesle, G., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.016 · Cited by 4
Self-citation
Platelet function testing: does a randomized controlled trial settle the debate?
Chandra, R. V., Chan, N., Leslie‐Mazwi, T. M., Mehta, B., & Hirsch, J. A. (2015) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2015-011954 · Cited by 4
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel
Li, S., Shi, Y., Wang, H., Zhang, W., & Liu, J. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1207-5 · Cited by 4
Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
Coons, J. C., & Miller, T. J. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1447 · Cited by 5
Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response
Good, R., McGarrity, A. M., James, T. E., Miller, H., McConnachie, A., Goodall, A. H., & Oldroyd, K. G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.021 · Cited by 4
ST Elevation Myocardial Infarction: Recent Advances and Updates
Ganjehei, L., Rashid, U. M., Payami, S., & Saal, A. (2014) · Future Cardiology · doi:10.2217/fca.14.46 · Cited by 4
Personalized Antiplatelet Therapy
Gurbel, P. A., Rafeedheen, R., & Tantry, U. S. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.01.012 · Cited by 4
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention
Lü, L., Wang, H., Chen, Y., Lin, W.-W., Wang, C., & Lin, C.-H. (2015) · Coronary Artery Disease · doi:10.1097/mca.0000000000000246 · Cited by 4
Most Important Outcomes Research Papers on Treatment of Stable Coronary Artery Disease
Bikdeli, B., Ranasinghe, I., Chen, R., Gupta, A., Lampropulos, J. F., Kulkarni, V., Mody, P. S., Dharmarajan, K., & Editor, F. T. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000310 · Cited by 4
Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account
Tantry, U. S., Mahla, E., Gesheff, M. G., & Gurbel, P. A. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.839382 · Cited by 4
Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial
Li, Y., Han, Y., Guan, S., Sun, Y., Guo, L., Yang, B., Zang, H., Jing, Q., Wang, X., Ma, Y., et al. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv024 · Cited by 4
Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals
Kimura, Y., Takano, K., Satoh, K., Aida, K., Kobayashi, T., & Ozaki, Y. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613488934 · Cited by 4
What have we learned from the ANTARCTIC trial?
Gurbel, P. A., & Tantry, U. S. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.167 · Cited by 4
Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting
Groß, L., & Sibbing, D. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.011 · Cited by 4
Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials
Xing, Z., Tang, L., Zhu, Z., Huang, J., Peng, X., & Hu, X. (2017) · Platelets · doi:10.1080/09537104.2017.1349306 · Cited by 4
Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study
Fanaroff, A. C., Kaltenbach, L. A., Peterson, E. D., Akhter, M. W., Effron, M. B., Henry, T. D., & Wang, T. Y. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007982 · Cited by 4
Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future
Khakimova, M. B., Komarov, A. L., Dobrovolsky, A. B., & Панченко, Е. П. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin2022170415 · Cited by 4
Mechanisms of thrombogenesis associated with diabetes mellitus: what defines the prognosis of invasive myocardial revascularization methods?
Bondarenko, I. Z., & Ширшина, И. А. (2013) · Diabetes Mellitus · doi:10.14341/2072-0351-95 · Cited by 4
Von Willebrand Factor Antigen Predicts Response to Double Dose of Aspirin and Clopidogrel by PFA‐100 in Patients Undergoing Primary Angioplasty for St Elevation Myocardial Infarction
Gianetti, J., Parri, M. S., Pina, F. D., Marchi, F., Koni, E., Caterina, A. D., Maffei, S., & Berti, S. L. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/313492 · Cited by 4
Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease
Nusca, A., Patti, G., & Sciascio, G. D. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9439-7 · Cited by 4

Authors: Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
Affiliations: Pitié-Salpêtrière Hospital (FR)
Hôpital de la Timone (FR)
Les Hôpitaux de Chartres (FR)
Centre Hospitalier Universitaire de Nîmes (FR)
Hôpital Lariboisière (FR)
Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Hôpital Rangueil (FR)
Hôpital Bichat-Claude-Bernard (FR)
HIA du Val-de-Grâce à Paris (FR)
ORCID: Collet, Jean-Philippe
Cuisset, Thomas
Rangé, Grégoire
Cayla, Guillaume
Elhadad, Simon
Pouillot, Christophe
Henry, Patrick
Motreff, Pascal
Carrié, Didier
Rousseau, Hélène
Aubry, Pierre
Sabouret, Pierre
Abtan, Jérémie
Barthélémy, Olivier
Beygui, Farzin
Silvain, Johanne
Montalescot, Gilles
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11-29
Volume: 367
Issue: 22
Pages: 2100-2109
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1209979
OpenAlex: W2145323902
Cited by: 887
References: 26
Citations by year: 2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
FWCI: 81.10
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
MeSH terms: Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks